EUVIMEDEUVIMED entdecken
Crossref

Modulation of PPAR-γ, SREBP-1c and inflammatory mediators by luteolin ameliorates β-cell dysfunction and renal damage in a rat model of type-2 diabetes mellitus

Syed Ilyas Shehnaz, Anitha Roy, Rajagopalan Vijayaraghavan, Senthilkumar Sivanesan, Natesan Pazhanivel

Molecular Biology Reports · 2023

DOI: 10.1007/s11033-023-08804-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Biology Reports, 2023. Verfasst von Syed Ilyas Shehnaz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha Nagar, Thandalam, C…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetes Mellitus, Experimental, Hyperglycemia. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Natural products have been recommended as a complementary therapy for type 2 diabetes mellitus (T2DM) due to constraints of safety and tolerability of existing anti-diabetic agents. Luteolin exhibits anti-diabetic and anti-inflammatory effects. Hence, the impact of luteolin on glucose homoeostasis and organ damage was investigated in high-fat diet (HFD) and streptozotocin (STZ) induced T2DM in rats. METHODS AND RESULTS: Male Wistar rats were maintained on HFD (provided 55% energy as fat) for 10 days. Subsequently, a single dose of 40 mg/kg STZ was injected intraperitoneally on the 11th day. Seventy-two hours after STZ administration, diabetic rats with established hyperglycemia (fasting serum glucose > 200 mg/dL) were randomized into different groups having six rats each and orally administered either 0.5% hydroxy propyl cellulose or pioglitazone (10 mg/kg) or luteolin (50 mg/kg or 100 mg/kg) once daily for 28 days, while continuing HFD for respective groups. Luteolin significantly reduced hyperglycaemia, homoeostasis model assessment (HOMA) of insulin resistance (HOMA-IR) levels, and improved hypoinsulinemia and HOMA of b-cell function (HOMA-B) in a dose-dependent manner. Increased TNF-α, IL-6 and NFκB levels in diabetic rats were significantly regulated. Additionally, luteolin significantly augmented PPAR-γ expression while attenuating sterol regulatory element binding protein-1c (SREBP-1c) expression. Histopathological scrutiny validated that luteolin effectively attenuated HFD-STZ-induced injury in pancreatic β-cells and kidneys to near normalcy. CONCLUSION: Our study showed that luteolin ameliorated hyperglycemia and improved hypoinsulinemia, β-cell dysfunction, and renal impairment in HFD-STZ-induced diabetic rats by attenuating inflammation and dysregulated cytokine secretion through modulation of PPAR-γ, TNF-α, IL-6 and NF-kB expression and down-regulation of SREBP-1c.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Diabetes Mellitus, ExperimentalHyperglycemiaRatsMaleAnimalsPPAR gammaSterol Regulatory Element Binding Protein 1LuteolinInsulinTumor Necrosis Factor-alphaInterleukin-6Rats, WistarBlood GlucoseGlucoseNF-kappa BKidneyStreptozocin

Stichwörter der Autor:innen

LuteolinNuclear factor-κBPPAR-γSREBP1cTNF-αType 2 diabetes mellitus

Substanzen

PPAR gammaSterol Regulatory Element Binding Protein 1LuteolinInsulinTumor Necrosis Factor-alphaInterleukin-6Blood GlucoseGlucoseNF-kappa BStreptozocin

Autor:innen und Institutionen

  • Department of Pharmacology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha Nagar, Thandalam, Chennai, Tamil Nadu, 602105, India. syedshehnazilyas.smc@saveetha.com.
  • Department of Pharmacology, Center for Transdisciplinary Research, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu, 600077, India.
  • Department of Research and Development, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu, 602105, India.
  • Department of Biosciences, Institute of Biotechnology, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu, 602105, India.
  • Department of Veterinary Pathology, Madras Veterinary College, Chennai, Tamil Nadu, 600 007, India.

Zitieren

APA

Shehnaz, S. I., Roy, A., Vijayaraghavan, R., Sivanesan, S., & Pazhanivel, N. (2023). Modulation of PPAR-γ, SREBP-1c and inflammatory mediators by luteolin ameliorates β-cell dysfunction and renal damage in a rat model of type-2 diabetes mellitus. Molecular Biology Reports. https://doi.org/10.1007/s11033-023-08804-8

Vancouver

Shehnaz SI, Roy A, Vijayaraghavan R, Sivanesan S, Pazhanivel N. Modulation of PPAR-γ, SREBP-1c and inflammatory mediators by luteolin ameliorates β-cell dysfunction and renal damage in a rat model of type-2 diabetes mellitus. Molecular Biology Reports. 2023. doi:10.1007/s11033-023-08804-8

BibTeX
@article{Shehnaz2023,
  author = {Shehnaz, Syed Ilyas and Roy, Anitha and Vijayaraghavan, Rajagopalan and Sivanesan, Senthilkumar and Pazhanivel, Natesan},
  title = {Modulation of PPAR-γ, SREBP-1c and inflammatory mediators by luteolin ameliorates β-cell dysfunction and renal damage in a rat model of type-2 diabetes mellitus},
  journal = {Molecular Biology Reports},
  year = {2023},
  doi = {10.1007/s11033-023-08804-8}
}
Kostenlos starten →